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BACKGROUND: Juvenile pilocytic astrocytomas (JPA), a subgroup of low-grade astrocytomas (LGA), are common, heterogeneous and
poorly understood subset of brain tumours in children. Chromosomal 7q34 duplication leading to fusion genes formed between
KIAA1549 and BRAF and subsequent constitutive activation of BRAF was recently identified in a proportion of LGA, and may be
involved in their pathogenesis. Our aim was to investigate additional chromosomal unbalances in LGA and whether incidence of 7q34
duplication is associated with tumour type or location.
METHODS AND RESULTS: Using Illumina-Human-Hap300-Duo and 610-Quad high-resolution-SNP-based arrays and quantitative PCR
on genes of interest, we investigated 84 paediatric LGA. We demonstrate that 7q34 duplication is specific to sporadic JPA (35 of
53 – 66%) and does not occur in other LGA subtypes (0 of 27) or NF1-associated-JPA (0 of 4). We also establish that it is site specific
as it occurs in the majority of cerebellar JPA (24 of 30 – 80%) followed by brainstem, hypothalamic/optic pathway JPA (10 of
16 – 62.5%) and is rare in hemispheric JPA (1 of 7 – 14%). The MAP-kinase pathway, assessed through ERK phosphorylation, was
active in all tumours regardless of 7q34 duplication. Gain of function studies performed on hTERT-immortalised astrocytes show that
overexpression of wild-type BRAF does not increase cell proliferation or baseline MAPK signalling even if it sensitises cells to EGFR
stimulation.
CONCLUSIONS AND INTERPRETATION: Our results suggest that variants of JPA might arise from a unique site-restricted progenitor cell
where 7q34 duplication, a hallmark of this tumour-type in association to MAPK-kinase pathway activation, potentially plays a site-
specific role in their pathogenesis. Importantly, gain of function abnormalities in components of MAP-Kinase signalling are potentially
present in all JPA making this tumour amenable to therapeutic targeting of this pathway.
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Juvenile pilocytic astrocytomas (JPA) account for 60–80% of
paediatric low-grade astrocytomas (LGA), the most common
paediatric brain tumour, and thus are the most frequently
encountered subtype of brain neoplasm in children under the
age of 19 years. They are classified according to the World Health
Organisation (WHO) as WHO grade I (Louis et al, 2007), and
occur sporadically throughout childhood or arise in up to 15–40%
of children affected with neurofibromatosis type 1 (NF1; Pollack
and Mulvihill, 1997). JPA exhibit distinct features, readily
distinguishable from their other LGA counterparts, including
clinical course and molecular characteristics, and have better
prognosis in affected children (Gajjar et al, 1997; Ishii et al, 1998;
Cheng et al, 2000; Tada et al, 2003; Broniscer et al, 2007; Fisher
et al, 2008).
Even though they share similar histology, there is heterogeneity
between sporadic JPA in terms of localisation, radiologic features,
histologic atypia and clinical behaviour, all of which argue for the
possibility of genetic disparity between potential JPA subgroups.
Typically, JPA occur as exophytic cerebellar tumours, however,
they can also arise in the brain stem or the optic pathway, where
they behave more aggressively than NF1-associated JPA (Grill et al,
2000), or, more rarely, in the cerebral hemispheres. Maximal
surgical resection is the mainstay of therapy, and failure to achieve
it remains the main therapeutic concern. Although cerebellar
JPA are readily amenable to complete surgical resection, in other
less anatomically accessible locations, surgery may result in the
persistence of residual disease, which can require further therapy
for tumour control, and ultimately lead to increased morbidity/
mortality. In addition, some of these extracerebellar JPA seem less
circumscribed and may exhibit atypical pathologic features,
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leading to pathologic misdiagnosis, including into higher grade
tumours.
Until recently, the few genetic abnormalities documented in
JPA mainly identified chromosomal gains of 7q and trisomy of
chromosomes 5, 7 or 8 in some tumours (White et al, 1995; Rickert
and Paulus, 2004; Wemmert et al, 2006). Recently several
consecutive papers described duplication of 7q34 in LGA including
JPA (Bar et al, 2008; Deshmukh et al, 2008; Jones et al, 2008; Pfister
et al, 2008; Sievert et al, 2008). However, the data reported are
conflicting regarding the subgroup of LGA affected by this genetic
event, the size of the duplication and its anatomical localisation
within the brain. Indeed, Deshmukh et al (2008) identified
amplification of 7q34 in 8 of 10 cerebellar JPA at 138151200–
139456000, which included HIPK2, a potential gene of interest. The
authors further showed using an immunohistochemical approach
that overexpression of HIPK2 was more frequent in LGA than in
high-grade gliomas, and that it was more common in infratentorial
tumours. Their silencing of HIPK2 in U87 (a glioblastoma (GBM)
cell line) decreased the cells proliferation rate. Pfister et al (2008)
identified duplication of 7q34 within 139186224–140156951 in 30
of 66 (45.5%) paediatric LGA. This region included BRAF, a gene
which was not in the genetic interval described in Deshmukh et al
(2008). The authors confirmed the absence of previously described
BRAF oncogenic mutations in their sample set, and showed that
silencing of BRAF in a LGA cell line decreased cell proliferation
rates. However, based on lower resolution BAC arrays, they did not
precisely map the genetic region missing other genes potentially
critical in the pathogenesis of LGA, including HIPK2. In addition,
data from this report suggest that LGA other than JPA may
harbour 7q34 duplication and that this genetic alteration is more
frequent in non-cerebellar tumours.
Recent reports have indicated a central role for the mitogen-
activated protein kinase (MAPK) pathway in the tumorigenesis of
pilocytic astrocytomas and showed that duplication at 7q34 leads
to a fusion between KIAA1549 and BRAF resulting in constitutive
activation of the BRAF kinase (Jones et al, 2008; Sievert et al,
2008). In particular, Jones et al (2008) focused on JPA and describe
a tandem duplication at 7q34 producing a transforming BRAF
fusion gene in 29 of 44 tumours (66%), and V600E point mutation
of BRAF in two further cases. Sievert et al indicated that 7q34
duplication occurs in 17 of 22 JPA but also report it in 3 of
6 diffuse astrocytomas (LGA grade II).
To determine the specificity of 7q34 duplication to a given
subgroup of LGA and identify additional genetic aberrations in
tumours that do not carry this duplication, we investigated 115
paediatric brain tumour samples including 57 JPA, and 27 diffuse
astrocytomas (Tables 1, 2a and b). Our data indicate that 7q34
duplication is exclusive to JPA and a hallmark of specific
anatomical localisations of these tumours within the brain. We
identify additional genetic abnormalities in JPA that do not
harbour 7q34 duplication, which may help shed light on their
pathogenesis. Data from gain of function analysis in immortalised
astrocytes further confirm that increased expression of wild-type
BRAF is unable to cause malignant transformation on its own
however may contribute to an increased response to exogenous
triggering of membrane receptors. Moreover, we show that the
MAPK pathway is active in all JPA regardless of 7q34 duplication
and that all of these tumours may be amenable to therapeutic
targeting of this pathway.
MATERIALS AND METHODS
Samples
All samples were obtained with informed consent after approval
of the Institutional Review Board of the respective hospitals they
were treated in, and independently reviewed by senior paediatric
neuropathologists (SA, CH, ZH) according to the WHO guidelines
(Kleihues et al, 2002). A total of 115 paediatric brain tumours
(average 9.4±4.7 years) were analysed (Tables 1, 2a and b);
57 JPA (53 sporadic, 4 from NF1 Patients), 27 diffuse astrocytomas
(grade II), 1 grade II ependymoma, 5 grade I gangliogliomas and
25 high-grade astrocytomas (HGA) were included. There were no
pylomixoid variants within the JPA included within this study. All
samples were taken at the time of the first surgery before further
treatment, when needed. Tissues were obtained from the London/
Ontario Tumor Bank, and from collaborators in Montreal, Toronto
and Hungary.
DNA extraction and hybridisation, SNP analysis
DNA from frozen tumours was extracted as described previously
(Wong et al, 2006). For SNP analysis, DNA (250 ng) from 40
samples was assayed with the Human Hap300-Duo (N¼ 28) and
the 610-Qad (N¼ 16) genotyping beadchips according to the
recommendations of the manufacturer (Illumina, San Diego, CA,
USA). These BeadChips enable whole-genome genotyping of
respectively over 300 000 and 610 000 tagSNP markers derived
from the International HapMap Project (www.hapmap.org) with a
mean intermaker distance of 10 and 5 kb respectively. Image
intensities were extracted using Illumina’s BeadScan software.
Data for each BeadChip were self-normalised using information
contained within the array. Penn-CNV (Wang et al, 2007) and
GqCNV (D Serre et al, unpublished) algorithms were applied on
the genotype data derived from the 40 LGA. Only the alterations
that were detected by both algorithm and that contained more than
5 consecutive SNPs were considered in this study. They were
further confirmed by visualisation in the BeadStudio.
Validation of copy number changes by quantitative
real-time PCR
Quantitative real-time PCR (q-PCR) was done on an ABI-Prism
7000 sequence detector (Applied Biosystems, Bedford, MA, USA)
using a SYBR Green kit (Applied Biosystems). The target locus
from each tumour DNA was normalised to the reference, Line-1 as
previously described (Wong et al, 2006; Supplementary Table 1).
Cell lines, antibodies and transfections
hTERT-immortalised human astrocytes (kind gift of Dr A Guha,
Labbatt Brain Tumour Research Centre, Ontario, Canada) were
grown and transfected with 2 mg of plasmid DNA encoding wild-
type C-Myc-Braf using Fugene 6 (Roche, Mississauga, ON, Canada)
as previously described (Shi et al, 2004). Unless stated otherwise, all
antibodies used were obtained from Cell Signaling (Danvers, MA,
USA). Transfected cells were used at 0, 48 and 72h posttransfection.
HIPK2 plasmids were generously provided by Dr Gabriella D’Orazi
(Regina Elena Cancer Institute, Rome, Italy), and BRAF plasmids by
Dr Richard Marais (Cancer Research, London, UK).
Western blot and immunofluorescence analysis
Extracts were prepared from cell pellets and western blot analysis
performed on total lysates as previously described (Jabado et al,
1998; Rajasekhar et al, 2003). Cross-reactivity was visualised by
ECL chemiluminescence (Amersham) on a phosphorimager. For
immunofluorescence analysis images were acquired using a Retiga
1300 digital camera (QIMAGING) and a Zeiss confocal microscope.
Immunohistochemical analysis
Immunohistochemical analyses for phospho-Erk (pErk), were
performed and the slides scored as previously described (Faury
et al, 2007).
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[3H]Thymidine incorporation assay
DMEM (10ml) containing 7.4 kBq (0.2mCi) of [methyl-3H]thymidine
(Amersham Pharmacia Biotech Europe, Freiburg, Germany; Batch
215, 65CimM) were added to each microplate well. Experiments were
done in triplicate at least three times with identical results.
RESULTS
Copy number variants in 40 LGA
To chart genomic alterations in our sample set, we first performed
a high-resolution genome-wide screen of the samples using the
Table 1 Characteristics of the 53 sporadic juvenile pilocytic astrocytomas (JPA) included in the study
Patients
Age
(years) Location
HIPK2
(qPCR)
BRAF
(qPCR) SNP array
Amplification
of 7q34 pERK (IHC) BRAFV600E
Cerebellar JPA (n¼ 30)
1 6 Cerebellar ND ND 7q34 amp Y ND ND
2 6 Cerebellar ND ND 7q34 amp Y ND ND
3 6 Cerebellar ND ND 7q34 amp Y ND ND
4 6 Cerebellar ND ND 7q34 amp Y ND ND
5 6 Cerebellar ND ND 7q34 amp Y ND ND
6 6 Cerebellar ND ND 7q34 amp Y ND ND
7 6 Cerebellar ND ND 7q34 amp Y ND ND
8 6 Cerebellar ND ND 7q34 amp Y ND ND
9 4 Cerebellar A A 7q34 amp Y Pos WT
10 4 Cerebellar A A 7q34 amp Y Pos WT
11 4 Cerebellar N N N N Pos WT
12 4 Cerebellar A A 7q34 amp Y Pos WT
13 4 Cerebellar N N ND N Pos ND
14 4 Cerebellar A A 7q34 amp Y Pos WT
15 4 Cerebellar ND ND N N Pos ND
16 4 Cerebellar A A 7q34 amp Y Pos WT
17 3 Cerebellar N N N N Pos WT
18 6 Cerebellar N N N N Pos BRAFV600E
19 11 Cerebellar A A 7q34 amp Y Pos WT
20 11 Cerebellar A A 7q34 amp Y Pos WT
21 6 Cerebellar A A ND Y Pos WT
22 11 Cerebellar A A ND Y Pos WT
23 9 Cerebellar N N ND N Pos WT
24 4 Cerebellar A A ND Y Pos WT
25 8 Cerebellar A A ND Y Pos WT
26 2 Cerebellar A A ND Y Pos WT
27 9 Cerebellar A A ND Y Pos WT
28 16 Cerebellar A A ND Y Pos WT
29 2 Cerebellar A A ND Y Pos WT
30 14 Cerebellar A A ND Y Pos WT N¼ 24/30
Brainstem, hypothalamus and optic pathway (OP) JPA (n¼ 16)
31 18 Brainstem N N ND N Pos ND
32 6 Brainstem N N ND N Pos ND
33 3 Brainstem N N ND N Pos ND
34 1 Brainstem A A 7q34 amp Y Pos WT
35 9 Brainstem A A 7q34 amp Y Pos WT
36 4 Brainstem A A 7q34 amp Y Pos WT
37 6 Brainstem A N ND Y-HIPK2 Pos WT
38 6 OP A A ND Y Pos ND
39 12 OP A A ND Y Pos ND
40 11 OP A A ND Y Pos WT
41 6 OP ND ND N N ND ND
42 6 OP ND ND 7q34 amp Y ND ND
43 3 OP A A ND Y Pos WT
44 7 OP A A 7q34 amp Y Pos ND
45 6 OP ND ND N N ND ND
46 6 OP ND ND N N ND ND N¼ 10/16
Hemispheric JPA (n¼ 7)
47 6 Parietal ND ND N N ND ND
48 10 Parietal N N N N Pos WT
49 13 Occipital lobe N N N N Pos WT
50 6 Temporal A N ND Y-HIPK2 Pos WT
51 4 Occipital N N ND N Pos WT
52 6 Temporal ND ND N N ND ND
53 15 Ventricular ND N N N Pos ND N¼ 1/7
N¼ 35/53
N¼ negative; A¼ amplified; ND¼ not done; WT¼wild type; Pos¼ positive; qPCR¼ quantitative real-time PCR; pERK¼ phospho-ERK; IHC¼ immunohistochemistry.
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SNP arrays. The copy number variant (CNV) analysis of the
resulting dataset generated on the Human Hap300-Duo and
610-Qad arrays gave similar results for both platforms. All samples
had at least one CNV and the overall frequency of CNVs according
to the chromosomal position showed that most tumours had
only focal abnormalities, some of them previously reported. Most
LGA did not have chromosome-wide gains or deletions, with
the exception of two JPA samples, which had gains of the whole
chromosome 7 (Supplementary Table 2). Regions with loss-
of-heterozygosity were rarely found in LGA. We found a single
region showing recurrent gain of 7q34 in 20 of 40 (50%) samples
(minimal common region of gain for all tumours on chromo-
some 7:138380901–140119915, NCBI Build 36.3; Figure 1). The
gain specifically corresponds to a chromosomal duplication,
according to the Illumina Plots. A total copy number of 3 was
inferred based of the logR ratio plot that is characterised by an
upward deflection from 0 to 0.35 and by a split in the heterozygous
allele frequencies (B-allele frequency measure) into two popula-
tions, one located at 0.67 (2 : 1 ratio) and the other at 0.33 (1 : 2
ratio; Figure 1). This gain in 7q34 is a somatic event as it was
present in the tumour and not in DNA from peripheral blood
taken from the same patients (n¼ 7), thus excluding a germ-line
segmental duplication (data not shown). It was not found in a set
of 1363 control DNA analysed with the Illumina Human-Hap 300K
platform (Hakonarson et al, 2007) or in the 25 HGA included in
this study.
Table 2a Characteristics of the other low-grade gliomas included in this study
Patients
Age
(years) Location Pathology
HIP2K
(qPCR)
BRAF
(qPCR)
SNP
array
Amplification
of 7q34 pERK (IHC)
BRAF
V600E
Optic pathway NF-1-associated JPA (n¼ 4)
54 7 Optic pathway JPA/NF1 ND ND N N ND ND
55 7 Optic pathway JPA/NF1 ND ND N N ND ND
56 7 Optic pathway JPA/NF1 ND ND N N ND ND
57 7 Optic pathway JPA/NF1 ND ND N N ND ND
Other low grade gliomas (n¼ 33)
58 6 Parietal lobe Diffuse astrocytoma ND ND N N ND ND
59 7 Posterior fossa Diffuse astrocytoma ND ND N N ND ND
60 2 Posterior fossa Diffuse astrocytoma N N ND N Pos ND
61 14 Temporal lobe Diffuse astrocytoma N N ND N Pos ND
62 10 Temporal lobe Diffuse astrocytoma N N ND N Pos ND
63 0.25 Temporal lobe Diffuse astrocytoma A N ND Y-HIP2K Pos WT
64 6 Posterior fossa Diffuse astrocytoma ND ND N N ND ND
65 13 Posterior fossa Diffuse astrocytoma N N ND N ND ND
66 6 Temporal lobe Diffuse astrocytoma N N ND N ND ND
67 5 Fourth ventricule Diffuse astrocytoma N N ND N ND ND
68 2 Parietal lobe Diffuse astrocytoma N N ND N ND ND
69 14 Posterior fossa Diffuse astrocytoma N N ND N ND ND
70 12 Posterior fossa Diffuse astrocytoma N N ND N ND ND
71 11 Temporal lobe Diffuse astrocytoma N N ND N ND ND
72 10 Temporal lobe Diffuse astrocytoma N N ND N ND ND
73 7 Temporal lobe Diffuse astrocytoma N N ND N ND ND
74 9 Posterior fossa Diffuse astrocytoma N N ND N ND ND
75 12 Parietal lobe Diffuse astrocytoma N N ND N ND ND
76 15 Temporal lobe Diffuse astrocytoma N N ND N ND ND
77 2 Posterior fossa Diffuse astrocytoma N N ND N ND ND
78 9 Parietal lobe Diffuse astrocytoma N N ND N ND ND
79 18 Temporal lobe Diffuse astrocytoma N N ND N ND ND
80 5 Brainstem Diffuse astrocytoma N N ND N ND ND
81 3 Brainstem Diffuse astrocytoma N N ND N ND ND
82 2 Hippocampus Diffuse astrocytoma N N ND N ND ND
83 11 Hipothalamus Diffuse astrocytoma N N ND N ND ND
84 14 Posterior fossa Diffuse astrocytoma N N ND N ND ND
85 6 Frontal lobe Ganglioglioma ND ND N N ND ND
86 6 Brainstem Ganglioglioma ND ND N N ND ND
87 3 Temporal lobe Ganglioglioma N N N N Pos WT
88 16 Hippocampus Ganglioglioma N A N N Pos WT
89 1 Hippocampus Ganglioglioma N N N N Pos M
90 18 Cauda equina Ependymoma N N N N Pos WT
JPA¼ juvenile pilocytic astrocytoma; M¼V600E mutation; NF1¼ neurofibromatosis 1; SNP¼ single nucleotide polymorphism; qPCR¼ quantitative real-time PCR;
pERK¼ phospho-ERK; IHC¼ immunohistochemistry; N¼ negative; A¼ amplified; ND¼ not done; WT¼wild type; Pos¼ positive; M¼mutated.
Table 2b Clinical characteristics of samples from children with high-rade
astrocytomas included in this study
Number of patients 25
Gender
Male 14
Female 11
Median age 12 years (10–18 months)
WHO classification
Astrocytomas grade IV 18
Astrocytoma grade III 7
Tumor site
Supratentorial 18
Infratentorial 6
Mixed 1
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7q34 duplication involves both BRAF and HIPK2 genes and
is more frequent in extrahemispheric JPA
To validate amplification of the genetic interval we identified, DNA
was extracted from 17 samples analysed by SNP arrays and an
additional independent set of 55 samples including 22 JPA (Tables
1, 2a and b). We performed quantitative real-time PCR (qPCR) on
genes included within (HIPK2 – homeodomain-interacting protein
kinase 2; TBXAS1 – thromboxane synthetase 1), at the edge (BRAF)
and located just after (MRPS33) the interval of interest (Figure 1).
The resulting profiles further confirm those obtained by SNP
arrays and show that 26 of 72 samples have a detectable
amplification of HIPK2, TBXAS1 and BRAF, and that most samples
have normal copy number of MRPS33, which was located just
outside of the genetic interval of interest on chromosome 7q34
(Figures 1 and 2; Tables 1, 2a and b). Levels of messenger RNA for
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Figure 1 Duplication of 7q34 visualised using BeadStudio. (A) Chromosome-wide data showing duplication at 7q34 through the increase in the log R
ratio values (top) and split in the B allele frequencies (bottom) plotted for each SNP for one JPA sample (Patient 10; Table 1). (B) Zoom-in showing genes
included within the region of interest. (C) Detailed view of the 7q34 locus amplified in each of the 20 JPA samples. Genes within and outside the region of
interest are shown on the left. Genes we further used to validate duplication within this dataset and an additional dataset of 35 tumours are bolded.
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BRAF and HIPK2 were also tested using quantitative RT-PCR, as
previously described (Faury et al, 2007; Haque et al, 2007),
in seven samples with 7q34 duplication, and were in the range of
1.7–5 (data not shown).
Based on concordant results we considered the amplification of
HIPK2, TBXAS1 and BRAF by qPCR analysis to reflect duplication
of the 7q34 region. We thus combined SNP and qPCR data, and
further determined the incidence of 7q34 duplication based on
histology, for example, sporadic JPA (N¼ 53), NF1-associated JPA
(N¼ 4), diffuse astrocytomas (N¼ 27) and the other paediatric
brain tumours (N¼ 31). 7q34 duplication was only present in
sporadic JPA. Indeed, it was identified in 35 of 53 (66%) JPA, and
was absent in NF1-associated JPA and the other brain tumours
(Tables 1, 2a and b; Figure 2). Remarkably, this duplication was
more prevalent in tumours originating from specific sites within
the brain. In this regard, we found this amplification in 24 of
30 (80%) of cerebellar and 10 of 16 (62.5%) of brainstem/
hypothalamic/optic-pathway JPA, whereas only 1 of 7 of hemi-
spheric JPA had this duplication, which did not include BRAF
(Tables 1, 2a and b; Figure 2; Po0.001). We also sequenced BRAF
in 52 samples and found point mutations affecting the hot spot
codon 600 in exon 15 of BRAF, V600E (an activating mutation
previously described in melanomas and other cancers (Wan et al,
2004)) only in 1 JPA and 1 grade II ganglioglioma (Tables 1, 2a and
b; Supplementary Table 3) in keeping with previous studies
(Jeuken et al, 2007; Jones et al, 2008; Pfister et al, 2008).
Copy number variants in JPA without 7q34 duplication
We investigated genetic aberrations occurring specifically in JPA not
carrying 7q34 duplication analysed by SNP arrays (N¼ 10) and
identified recurrent abnormalities (Table 3). Amplification of 19p13
including killer receptor inhibitory genes (KIR) genes regulating the
activity of natural killer cells within the immune system was
identified in 5 of 10 JPA. A recurrent region of amplification at
12p11.21 was also identified in 7 of 10 JPA and 2 of 5 grade II LGA.
It includes genes with unknown function and OVOS2, a gene similar
to ovostatin, a proteinase inhibitor involved in innate immune
responses. These data suggest that genes involved in immune
modulation may be important in the pathogenesis of another
subgroup of JPA, which does not harbour 7q34 duplication.
The MAPK pathway is activated in all JPA regardless of
7q34 duplication
To assess whether BRAF amplification in the absence of mutation
can be correlated with increased activity of the RAF/MEK/ERK
pathway, we used immunohistochemical analysis based on
antibodies against the phosphorylated (activated) form of
ERK1–2 (pERK). Sections from samples for which we had fixed
paraffin embedded slides were tested for pERK (Tables 1, 2a and b;
Figure 3) immunoreactivity and scored as previously described
(Faury et al, 2007). Results show that the astrocytic component of
all JPA stained positively for pERK. This result indicates that the
MAPK pathway is triggered in LGA, including JPA, regardless of
BRAF copy number status or activating mutation.
Functional characterisation of BRAF and/or HIPK2
overexpression in immortalised mature astrocytes
To assess the potential of increased levels of wild-type BRAF
to drive increased activity of mitogenic pathways in cells of
glial origin we used hTERT-immortalised astrocytes (Kamnasaran
et al, 2007) as recipients of transient overexpression of genes
from the 7q34 region, wild-type (WT) BRAF, HIPK2 or both.
Mutant V600E BRAF was used as a positive control for trans-
formation of astrocytes. Transfection efficiency was estimated by
immunofluorescence analysis against the C-Myc and FLAG tags to
be approximatelyB40–50% at 48, 72 and 96 h (Figure 4A and B).
No foci of transformation or morphological changes were observed
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Figure 1 Continued.
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in cells transfected with WT constructs, whereas transformation
foci were readily distinguishable in V600E transfectant cells.
Proliferation assays revealed no change in growth of cells
overexpressing of BRAF, HIPK2 or both, compared to their
mock-transfected controls (Figure 4C). Similarly, overexpression
of BRAF had no discernible effect on the baseline level of ERK
expression or phosphorylation (Figure 4D). Indeed, in serum
starved EV and C-Myc-BRAF transfectant cells pERK was similar
in intensity in both settings, in keeping with previous findings in
COS cells (Ciampi et al, 2005). Remarkably, exposure of BRAF
overexpressing cells to ligands of the epidermal growth factor
receptor (EGFR), such as transforming growth factor-a or EGF
increased pERK levels by a mean of B5.9-fold relative to 2.3-fold
in empty-vector transfectants (mean of three distinct experiments,
Figure 4D). These results indicate that although BRAF over-
expression may not be sufficient to drive proliferative responses of
astrocytic cells it may sensitise them to exogenous growth factors.
DISCUSSION
We show that somatic duplication of 7q34 in LGA is specific to
JPA. We also establish that its prevalence varies with the site of
origin within the brain of the JPA, and is more frequent in
cerebellar (24 of 30 – 80%) followed by brainstem and optic
pathway tumours (10 of 16 – 62.5%), whereas it is rare in
hemispheric JPA (1 of 7 – 14%; Tables 1, 2a and b; Figures 1
and 2). Our analysis and the several validation steps we performed
characterise this region with increased precision compared to the
recently published concurrent studies, which missed either BRAF
or HIPK2 (Deshmukh et al, 2008; Jones et al, 2008; Pfister et al,
2008) and confirm that 7q34 amplification includes both BRAF and
HIPK2 in as many as 34 of 35 JPA samples. We identify additional
genetic regions in JPA without 7q34 duplication (Table 3) and
show that most genes within these regions are modulators of the
immune system.
Specificity of 7q34 duplication to JPA and its prevalence in
infratentorial tumours contrast with previous reports alluding that
7q34 duplication may be present in non-JPA LGA (Deshmukh
et al, 2008; Pfister et al, 2008; Sievert et al, 2008) and is more
frequent in non-cerebellar LGA (Pfister et al, 2008; Sievert et al,
2008). Deshmukh et al showed 7q34 duplication in 8 of 10
cerebellar JPA and further used increased HIPK2 expression on
tissue microarray as a surrogate for marker for this genetic event.
Other molecular events, distinct from 7q34 duplication, may lead
to HIPK2 overexpression (Sombroek and Hofmann, 2009) and may
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Figure 2 HIPK2, TBXAS1, BRAF and MRPS33 copy number in the brain tumours included in this study. DNA qPCR-based copy number for HIPK2,
TBXAS1, BRAF and MRPS33 are plotted. The cut-off for DNA copy number was set using the mean of ±2 s.d. (plotted lines) against MRPS33, which was
located after the genetic interval of interest (Figure 1).
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account for increased HIPK2 levels in tumours other than JPA. We
chose to validate the genetic interval we identified through
concordant increased copy number by qPCR of three consecutive
genes within it (HIPK2, TBXAS1, BRAF) in a large number of
samples, and thus show specificity of 7q34 duplication to JPA. The
lower resolution BAC-arrays used by Pfister et al led them to
underestimate the size of the duplication (0.94Mb instead of the
B1.74Mb, we and others describe) and might have led the authors
to miss this duplication in a number of cerebellar JPA samples.
Indeed, when we revisited data collectively published by the other
groups we found that JPA within the cerebellum have the highest
incidence for this duplication. In addition, in Jones et al (2008),
which focused on JPA, the authors indicate 7q34 duplication might
be more prevalent in infratentorial tumours, also in keeping with
Table 3 Genomic alterations in 10 JPA with no 7q34 duplications and 5 grade II astrocytomas
Minimal common region
Cerebellar
Brainstem
and optic
Hemi-
spheric Grade II
Chr Start End Nb SNP Size (kb) JPA pathway JPA JPA astrocytoma Genes
Homozygous deletions
1p36.13 17085956 17155012 11 69056 4 1 1 LOC100129182, TRNAN2, CROCC
1q21.2 147282617 147427061 15 144444 2 FJL12528, ECM1, FJ13544, TSRC1, MCL1,
ENSA
2p16.2 52995459 53070421 10 1 LOC402072
2q31.2 180123158 180129913 11 6755 1 1 ZNF385B
2q13 110201336 111021091 48 819755 1 1 Mall, NPHP1, FLJ, RGPD6, RGPD7
3p21.3 37954886 37961253 15 6367 1 2 CTDSPL
3p21.1 53003023 53021256 13 18233 1 1 SFMBT1
3q28 191217916 191221750 11 3835 3 2 CCD50
4q13.2 69064675 69163188 36 98513 1 1 1 UGT2B29P, UGT2B17, LOC100132651
4q34.1 173218118 173236491 105 18373 2 GALNT17
5p15.33 812485 873185 17 60700 1 2 ZDHHC11B, ZDHHC11
5q15 97053242 97121798 8 1 LOC391813
5q35.3 180307066 180363775 11 56709 1 1 BTNL8, LOC, BTNL3
7q11.22 67054161 67482237 54 1 LOC441249
8p23.1 12257261 12388979 16 131719 2 ZNF705C, FAM, FAM,
9p11.2 44683090 44770712 20 87623 2 1 1 LOC
11q11 55124465 55209499 49 85035 1 1 OR4C11, OR4P4, OR4S2, OR
11q11 55447435 55484857 8 1 OR5I1, OR10AF1P, OR10AK1P
12p13.31 9526879 9607393 15 80515 3 2 Ovostatin
17p11.2 18292126 18398047 9 105922 1 1 NOS2B, FAM, LOC
19q13.2 46047894 46075668 22 27774 2 CYP2A6, CYP2A7
19q13.41 56230373 56263967 8 1 KLK13
20q13.2 52080333 52088118 23 7786 2 BCAS1
21q21.3 26136162 26176988 8 1 APP
Chromosomal amplifications
1p31.1 74447282 74631475 16 1 TNNI3K
1q43 234665731 234752676 84 86946 2 EDARADD, ENO1P, LGALS8
2p11.2 86152633 86343699 20 1 POLR1A, FLJ20758, IMMT, MRPL35
4p12 47678100 47893952 50 139606 1 NPAL1, TXK, TEC
4q12 54076102 55611307 88 1 FIP1L1, LNX1, CHIC2, GSH-2, PDGFRa,
KIT
5q35.3 178337857 178528476 30 1 GRM6, ZNF354C, LOC645944,
ADAMTS2
5q11.2 53507913 53670668 128 162756 1 ARL15
6q27 168091860 168319676 209 227817 2 1 MLLT4, LOC100128124, KIF25, FRMD1
8p12-
8p11.23
38405382 38873687 41 2 FGFR1, FLJ43582, TACC1
8p23.1 8102456 8182850 26 80395 1 FLJ10661, LOC1001
10q11.22 47007374 47167032 82 74264 2 1 LOC340844, LOC728684, ANTXRL
10q26.3 135116379 135202003 14 2 Sprn, OR6LP2, LOC399832, OR7M1P
12p13.31 7895025 8014573 56 119549 1 SLC2A14, LOC, NANOGP1, SLC2A3,
NECAP1
12p11.21 31157554 31300846 55 143293 3 2 2 2 LOC100132881, OVOS2, LOC441632
12q14.2 62294703 62415375 7 1 FLJ32949, LOC390338
14q11.2 19283777 19493705 28 209929 1 All olfactory receptors
14q24.1-
14q24.2
69202898 69470896 32 1 KIAA0247, SFRS5, SLC10A1, RPL7AP6,
SMOC1
15q11.2 19359417 19523964 26 164548 1 LOC, OR11J2P, OR11J5P
15q26.3 99310512 99791921 204 481410 1 LRRK1, CHSY1, SELS, SNRPA1, PCSK6
17q25.3 74877129 74905197 48 28069 1 LOC, HRNBP3
19q13.31 47948855 48150403 26 201549 2 Pregnancy specific beta-1-glycoproteins
19q13.42 59971240 60054671 14 83432 1 3 2 KIR2DL1-4, KIR3DP1, KIR3DL1, KIR2DS1-4
20p13 1593502 1663448 41 69947 1 LOC
21q22.2 39823301 39835430 15 12130 1 LOC
22q11.23 23991725 24240667 94 248943 1 IGLL3, LRP5L, LOC, CRYBB2P1
22q11.21 17257787 17388108 73 130322 1 LOC, DGCR6, PRODH, DGCR5
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our data. They also show that one sample was classified as a grade
II astocytoma; however, the child had prolonged disease-free
survival more in keeping with a diagnosis of JPA. This
misclassification might also account for the findings of 7q34
duplication in some non-JPA LGA in the study by the other groups
(Deshmukh et al, 2008; Pfister et al, 2008; Sievert et al, 2008). The
central review of samples by senior paediatric neuropathologists
we performed has been shown to increase reproducibility of
neuropathologic classification of tumours (Pollack et al, 2003) and
may account for increased accuracy in our dataset. Our findings
and these from recent studies alluding to the presence of different
molecular signatures in sporadic JPA based on its region of origin
(Sharma et al, 2007) make it tempting to speculate that, like CNS
ependymoma (Taylor et al, 2005), variants of JPA might arise from
a unique site-restricted progenitor cell.
RAF kinases are components of a conserved signalling pathway
that regulates cellular responses to extracellular signals (Wan et al,
2004). Their role in glioma formation, and the role of the MAPK
cascade they trigger, have been identified in tumour samples and
further confirmed in mouse models (Jeuken et al, 2007; Pritchard
et al, 2007; Lyustikman et al, 2008; Pfister et al, 2008). NF1 encodes
for a Ras-GTPAse and its loss of function may lead to activation of
Ras/RAF signalling and coincides with formation of indolent JPA
mainly within the optic pathway. Our exploration of immortalised
astrocytes show that overexpression of wild-type BRAF may not be
sufficient by itself to mediate the activation of the MAPK cascade.
In keeping with these data, only oncogenic BRAF mutations have
been implicated in tumours of epithelial (Rajagopalan et al, 2002)
and neuroectodermal origin (Brose et al, 2002; Pollock et al, 2003).
7q34 duplication in JPA was recently shown to produce novel
JPA with 7q34 duplication JPA without 7q34 duplication
P13
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Figure 3 The astrocytic component of all the brain tumours included in this study show MAPK pathway activation regardless of BRAF copy number.
Immunohistochemical analyses for phosphorylated ERK (pERK), used as a surrogate marker of MAPK pathway activation were performed for the 52 samples
included in this study for which formalin-fixed paraffin-embedded slides were available. Sections were stained using anti-pERK followed by detection using
the DAKO kit (red accounts for positive staining) and hematoxylin counterstaining. Staining intensity was scored as in (Faury et al, 2007; Haque et al, 2007).
Full characteristics of samples are provided in Tables 1, 2a and b.
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Figure 4 Functional analysis of BRAF and HIPK2 overexpression in hTERT-immortalised astrocytes. (A) Immunofluorescence analysis of hTERT-
immortalised astrocytes transfected with CMYC/BRAF or the empty vector (EV) at 48 h using an antibody recognising the C-MYC tag (red), BRAF (green)
and DAPI counterstaining (blue). (B) Immunofluorescence analysis of hTERT-immortalised astrocytes transfected with FLAG/HIPK2 or the EV at 48 h using
an antibody recognising the FLAG tag (red) and DAPI counterstaining (blue). (C) Proliferation of hTERT-immortalised astrocytes was assessed at 48, 72 and
96 h following transfection with mock, BRAF, HIPK2 or both genes. No difference in the rate of cell growth was observed between the transfectant cells.
Results represent the median of three separate experiments performed in triplicates. (C) Total cell extracts of hTERT-immortalised astrocytes transfected
with the empty-vector or C-Myc-tagged BRAF. Cells were serum starved overnight before protein lysate extraction. (D) Left panel: hTERT-immortalised
astrocytes were transiently transfected with CMYC/BRAF or the empty vector. Cells were serum starved overnight and total protein lysates extracted at
48 h posttransfection. Western blot analysis for C-Myc, BRAF, phopshoERK (pERK) and b-actin (loading control) was performed. Right panel: Empty-vector
(EV) and C-Myc/BRAF transfectant hTERT-immortalised astrocytes were stimulated with 200 ng of epidermal growth factor (EGF) for 5 and 15min. Total
cell lysates extracted at baseline (0) and following activation (5, 15min) with EGF were immunoblotted using antibodies against b-actin (loading control) and
phosphorylated ERK (pERK), C-Myc and BRAF. Note the shift of BRAF immunoreactive band following EGF activation which indicates phosphorylation of
the kinase and increase in its molecular weight. Importantly, increase in pERK levels relative to baseline following EGF stimulation was two fold higher in
C-MYC/BRAF transfectant cells than in EV transfectants. Results represent the median of three separate experiments (Po0.001).
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oncogenic BRAF fusion genes with transforming capacity (Jones
et al, 2008), similar to findings in radiation-associated papillary
thyroid cancer (Ciampi et al, 2005) where an intrachromosomal
inversion, and not duplication, let to this oncogenic event. These
data indicate that wild-type BRAF would be unlikely to induce
transformation. Tumours in which the duplication occurs without
this in-frame fusion or in patients with trisomy of the full
chromosome 7 require other mechanisms to activate BRAF and
induce oncogenesis. Intriguingly, our data suggest that all JPA
have active MAPK pathway regardless of 7q34 duplication
(Figure 3). In keeping with the importance of the MAPK pathway
in JPA genesis, two additional alternative mechanisms resulting in
MAPK activation were very recently identified in JPA (Jones et al,
2009). This group studied the 10 JPA for which V600E point
mutation of BRAF (2 of 44), clinical diagnosis of NF1 (3 of 44) or
the common BRAF fusion following 7q34 duplication (29 of 44)
could not be found (Jones et al, 2008). In one patient they found
tandem duplication at 3p25 producing an in-frame oncogenic
fusion between SRGAP3 and RAF1, a finding corroborated by a
concurrent group on additional patients with JPA and no clinical
NF1, 7q34 duplication or BRAF mutations (Forshew et al, 2009).
This genetic event bears striking resemblance to the common
KIAA1549 BRAF fusion event and the fusion protein includes the
Raf1 kinase domain, and shows elevated kinase activity when
compared with wild-type Raf1. Secondly, in one patient with JPA a
novel 3 bp insertion at codon 598 in BRAF mimics the hotspot
V600E mutation to produce a transforming, constitutively active
BRaf kinase (Jones et al, 2009). These findings further imply that
BRAF or RAF1 constitutive activation, achieved through different
genetic events, converge to activate the MAPK pathway and that
this pathway could be clinically targeted in all JPA.
Gains in 7q34 have been described in other cancers including
ovarian cancer. However these are amplifications and not
duplications and the region involved has some but no complete
overlap with the one identified in JPA. Also, genetic analysis of
medulloblastomas (Gilbertson and Ellison, 2008), ependymomas
(Taylor et al, 2005) and high-grade astrocytomas (our data) do not
identify 7q34 duplication in these tumours making this genetic
event specific to JPA. Unscheduled activation of the MAPK
pathway may lead to cellular senescence, which could function
to limit tumour development (Courtois-Cox et al, 2006). Therefore
we also postulate that oncogenic BRAF may cooperate with other,
presently unknown changes, to drive formation of a subset of JPA
at the same time it may drive activation of other pathways
including cellular senescence. Ultimately, this may make this
tumour less aggressive, similar to what is observed in melanocytes
where oncogenic BRAF mutations result only in naevi formation.
As complete surgical removal is the rule for cerebellar JPA, studies
compiling higher numbers of JPA, occurring in other locations, are
needed to establish whether 7q34 duplication is indeed associated
with improved progression-free survival, as well as the biological
mechanisms controlling these variables.
In summary, our studies suggest that the 7q34 region may play a
site-specific role in pathogenesis of JPA and that the involvement
of an active MAP kinase signalling pathway through oncogenic
BRAF and other RAF family members in this process is crucial.
They further emphasise the relevance of therapeutic targeting of
this pathway in all JPA. To avoid misdiagnosis and adapt therapies,
all infratentorial LGA should be screened by immunohistochem-
istry for active MAP kinase pathway (phosphorylated ERK) and
further tested for the presence of 7q34 duplication, then, in its
absence, 3p25 gain or BRAF mutation. Further functional
evaluation of genes included within this genetic interval, others
we identify herein, and others involved in the MAP kinase cascade
and their correlation in larger sample sets to the site of origin, age
of the patient and progression-free survival will help shed light on
the pathogenesis of JPA.
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